Corresponding data in 118 patients, (94 CML-CP and 24 CML-AP) receiving NGS were 53 (44.9%; single T315I mutation), 19 (16.1%; T315I and additional noncompound mutations), 14 (11.9%; other noncompound mutations), 12 (10.2%; compound mutations), and 20 (16.9%; no BCR-ABL1 mutation). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.